BioInvent International AB

BIX0

Company Profile

  • Business description

    BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

  • Contact

    Ideongatan 1
    LundSE-223 70
    SWE

    T: +46 462868550

    E: [email protected]

    https://www.bioinvent.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    122

Stocks News & Analysis

stocks

Acquisition a sign of weakness for overvalued ASX share

Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
stocks

ASX opportunities after earnings season

Finding value in an expensive market.
stocks

3 global ‘buy the dip’ candidates with wide moats

Does recent share price weakness spell opportunity in these three high-quality companies? Our analysts think so.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,120.9034.100.38%
CAC 407,908.6483.401.07%
DAX 4023,773.0874.930.32%
Dow JONES (US)45,834.22273.78-0.59%
FTSE 1009,285.191.900.02%
HKSE26,446.5658.400.22%
NASDAQ22,141.1098.030.44%
Nikkei 22544,768.12395.620.89%
NZX 50 Index13,208.3119.59-0.15%
S&P 5006,584.293.18-0.05%
S&P/ASX 2008,853.0031.600.36%
SSE Composite Index3,860.5010.09-0.26%

Market Movers